Malignant neoplasms of prostate (Q38926): Difference between revisions
From determinar.ia.br - Determine suas informações
Changed an Item |
Changed an Item |
||
| Property / Linked ICD 10 | |||
| Property / Linked ICD 10: C61 / rank | |||
Normal rank | |||
Latest revision as of 04:11, 13 August 2026
Prostate cancer contributes significantly to the overall cancer burden and is the most common malignant neoplasm in men. The number of cases has steadily increased over recent decades, partly due to rising life expectancy. Additional contributing factors include aspects of the Western lifestyle, such as high-calorie diets and reduced physical activity. Epidemiological data suggest that incidence rates vary among populations, with the highest rates observed in individuals of African descent, followed by those of European descent, while rates are lowest in some Asian populations. The impact of prostate-specific antigen (PSA) screening on mortality reduction is currently under evaluation. Histopathological diagnosis and grading remain critical components in the clinical management of prostate cancer.
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | 2C82 |
||
| English | Malignant neoplasms of prostate |
Prostate cancer contributes significantly to the overall cancer burden and is the most common malignant neoplasm in men. The number of cases has steadily increased over recent decades, partly due to rising life expectancy. Additional contributing factors include aspects of the Western lifestyle, such as high-calorie diets and reduced physical activity. Epidemiological data suggest that incidence rates vary among populations, with the highest rates observed in individuals of African descent, followed by those of European descent, while rates are lowest in some Asian populations. The impact of prostate-specific antigen (PSA) screening on mortality reduction is currently under evaluation. Histopathological diagnosis and grading remain critical components in the clinical management of prostate cancer. |
Statements
CID11:2C82
0 references
dki-india-2C82
0 references
Concluído
0 references
13 August 2026
0 references
